dc.description.abstract |
Background: Hepatitis E virus (HEV) often causing self-limiting hepatitis, appears to be a
global health issue specially in Low- or Middle-Income (LMIC) countries. Pregnant women are
more likely to experience severe morbidity and mortality, particularly, in South Asian countries
including Bangladesh. Its pathogenetic basis is still not clearly understood. Objectives: The
aim of the present study was to demonstrate the hepatitis E viral load, its genotypes, and IgG
immune responses against the HEV virus, and to find out the association of these parameters
with pregnancy related morbidity and mortality; for the purpose of determining HEV IgG
antibodies utilizing dried blood spots (DBS) samples to design and validate a modified Enzyme
linked Immunosorbent Assay (ELISA), to explore the molecular basis of binding affinities of
HEV ORF2 wild type and mutant peptide with HLA alleles, and to determine the effects of
mutation of capsid protein on disease severity using in-silico CD8
+
T cell epitope prediction.
Methods: One hundred and twenty-one women (pregnant, n = 57; non-pregnant, n = 64) with
acute HEV infected hepatitis, attending tertiary care hospitals in Dhaka and Chattogram cities
were enrolled in the study after collecting their respective sociodemographic and clinical data.
Biochemical analysis e.g., serum bilirubin, alanine transaminase (ALT) and aspartate
transaminase (AST) were carried out for all the samples. Seventy-eight HEV IgM-positive
samples were subjected to reverse transcription real-time quantitative polymerase chain reaction
(RT-qPCR) for estimation of viral copy number from their extracted RNA. Out of 62 real-time
PCR positive samples, Sanger sequencing of HEV ORF2 was carried out successfully on 32
samples after purification of PCR products. IgG antibody for HEV was determined by ELISA
and avidity indices were calculated. Dried Blood Spot (DBS) samples were prepared from HEV
patients (n = 45), and compared with healthy controls (n = 20) in order to determine HEV IgG
antibody by modified ELISA. Using the NetMHCpan 4.0 Server, epitopes of capsid protein
encoded by HEV ORF2 were predicted for CD8
+
T-cell. Both 9-mer peptide lengths and human
leukocyte antigen (HLA) alleles were chosen and submitted. Molecular docking and molecular
dynamics simulations were carried out for two common HLA alleles of Bangladesh. Results: In
the late acute phase of hepatitis, there were significant negative correlations between log HEV
copy number and log HEV IgG antibody index for both pregnant (r = -0.7971, p = 0.0002) and
non-pregnant (r = -0.9117, p = 0.0002) women. When HEV-induced hepatitis reached its late
acute phase, pregnant women revealed significantly greater serum log viral copy number and
lower IgG antibody indices than non-pregnant women (p=0.0196 and p=0.0303, respectively).
Additionally, compared to non-pregnant women, pregnant women with acute HEV hepatitis exhibited higher levels of cross-reactive IgG antibodies (p=0.0017). Four of the
five HEV hepatitis patients that expired were pregnant. DBS and plasma samples demonstrated
almost similar IgG antibody levels for HEV. At dilution 1:200, a highly significant correlation
between plasma and DBS sample absorbances was found (R
2
=0.98; p <0.001), demonstrating
real agreement between the two techniques. These procedures also showed linearity and showed
no influence of haematocrit on test performance. The genotype for HEV was discovered as
variant 1. A novel mutation, Q531L in 3 samples was identified. Significantly low levels of
ALT (p= 0.001) for mutant HEV ORF2 531
Leu
-containing peptide than that of wild type HEV
(ORF2 531
Gln
) was observed. The 531
Leu
containing epitope showed higher binding affinity
than 531
Gln
containing epitope for the HLA molecules. Conclusions: High viral load at the late
acute phase of hepatitis can be assumed to be resulting from low level of HEV IgG that renders
little neutralizing effect on HEV-infected pregnant women demonstrating higher morbidity/
mortality in genotype 1 HEV-infected pregnant women. A less- invasive collection strategy
with a low-cost lab detection ELISA method has been developed for determination of HEV IgG
by using DBS samples which is assumed to be much more promising nowadays. The binding
free energy profile of mutant 531
Leu
peptide with HLA alleles were considerably higher than
that of wild 531
Gln
peptide indicating the association of 531
Leu
mutation with less morbidity and
providing host protection. These results suggest that the Q531L mutation may be associated
with decreased viral load and less severity of disease. |
en_US |